Market Overview

Gabelli Downgrades Lexicon Pharmaceuticals To Hold


Analysts at Gabelli downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Buy to Hold.

Lexicon Pharma shares have dropped 27.43% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period.

Lexicon Pharma's shares closed at $1.64 yesterday.

Latest Ratings for LXRX

Dec 2020CitigroupUpgradesNeutralBuy
Nov 2020Gabelli & Co.UpgradesHoldBuy
Apr 2020CitigroupMaintainsNeutral

View More Analyst Ratings for LXRX
View the Latest Analyst Ratings


Related Articles (LXRX)

View Comments and Join the Discussion!

Posted-In: GabelliDowngrades Analyst Ratings

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at